Skip to Main Content

Skip Nav Destination

Poster Sessions| November 16, 2005

Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy.

Allan Lipton,

Allan Lipton *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Robert E. Coleman,

Robert E. Coleman *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Pierre Major,

Pierre Major *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Janet E. Brown,

Janet E. Brown *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Ker-Ai Lee,

Ker-Ai Lee *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Matthew Smith,

Matthew Smith *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Fred Saad,

Fred Saad *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

YinMiao Chen,

YinMiao Chen *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Yong Jiang, Hei,

Yong Jiang, Hei *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Richard Cook

Richard Cook *

(Intr. by Evangelos Terpos ) ¹Dept of Medicine, Penn State University, Milton S. Hershey Medical Center, Hershey, PA, USA; ²Dept of Oncology, Weston Park Hospital, Cancer Research Centre, Yorkshire Cancer Research Academic Unit of Clinical Oncology, Sheffield, England, United Kingdom; ³Dept of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada; ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada; ⁵Dept of Oncology, Massachusetts General Hospital, Boston, MA, USA; ⁶Dept of Oncology, Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, QC, Canada and ⁷Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Search for other works by this author on:

PubMed

Google Scholar

Blood (2005) 106 (11): 3456.

https://doi.org/10.1182/blood.V106.11.3456.3456

Abstract

BACKGROUND: Biochemical markers of bone metabolism provide valuable information about rates of bone turnover in patients with malignant bone disease. N-telopeptide of type I collagen (NTX) is released during osteolysis and is indicative of pathologic increases in bone resorption. Elevated NTX levels recently have been correlated with increased risks of skeletal-related events (SREs, defined as pathologic fracture, surgery to bone, spinal cord compression, hypercalcemia of malignancy, and the requirement for palliative radiotherapy), disease progression, and death in patients with bone metastases from solid tumors (

Coleman RE, et al. J Clin Oncol. 2005;23:4925–4935

;

Brown J, et al. J Natl Cancer Inst. 2005;97:59–69

).

METHODS: The current univariate analysis investigated the correlation between NTX levels at baseline and SREs (including palliative radiotherapy to bone) in patients with multiple myeloma who were treated with 4 mg zoledronic acid in a phase III clinical trial (

Rosen LS, et al. Cancer J. 2001;7:377–387

).

RESULTS: Forty-three patients had low NTX (< 50 nmol/mmol creatinine), 45 had moderate NTX (50 to < 100 nmol/mmol creatinine), and 18 had high NTX (≥ 100 nmol/mmol creatinine) at baseline. Patients with either moderate or high NTX at baseline had significantly increased risks of on-study SREs and significantly increased risks of experiencing their first SRE while on-study compared with patients with low NTX (Table). A similar correlation was also observed for pathologic fractures alone. The risk of first events was especially high in the high NTX group. There were no significant correlations between NTX levels and the requirement for palliative radiotherapy alone.

Hazard Ratios for Time to Onset and Occurrence of On-Study SRE Compared With Low (< 50 nmol/mmol creatinine) NTX (P Value)

	SRE		Pathologic fracture		Palliative radiotherapy
Baseline NTX level	Onset of first SRE	Any event	Onset of first event	Any event	Onset of first event	Any event
*50 to < 100 nmol/mmol creatinine.; † ≥ 100 nmol/mmol creatinine.
Moderate*	2.76 (.012)	2.26 (.003)	3.78 (.001)	2.98 (< .001)	1.21 (.777)	1.61 (.386)
High†	6.80 (< .001)	4.01 (.001)	8.87 (< .001)	5.35 (< .001)	3.23 (.095)	3.44 (.124)

	SRE		Pathologic fracture		Palliative radiotherapy
Baseline NTX level	Onset of first SRE	Any event	Onset of first event	Any event	Onset of first event	Any event
*50 to < 100 nmol/mmol creatinine.; † ≥ 100 nmol/mmol creatinine.
Moderate*	2.76 (.012)	2.26 (.003)	3.78 (.001)	2.98 (< .001)	1.21 (.777)	1.61 (.386)
High†	6.80 (< .001)	4.01 (.001)	8.87 (< .001)	5.35 (< .001)	3.23 (.095)	3.44 (.124)

Conclusions: Multiple myeloma patients with elevated baseline NTX levels have a significantly increased risk of experiencing SREs.

Author notes

Corresponding author

2005, The American Society of Hematology

2005

Sign in via your Institution

Supplemental data